炎性乳腺癌1例
Inflammatory Breast Cancer: A Case Report
DOI: 10.12677/ACM.2022.12101383, PDF,   
作者: 刘茹艳：西安医学院，陕西 西安；霍斌亮*：陕西省人民医院，陕西 西安
关键词: 炎性乳腺癌；新辅助放疗；乳腺癌改良根治术；Inflammatory Breast Cancer； Neoadjuvant Radiotherapy； Modified Radical Mastectomy
摘要: 目的：由于炎性乳腺癌发病罕见，且初始症状常为炎症表现，在诊疗过程中常常被误诊、漏诊，本文通过1例炎性乳腺癌新辅助化疗病例及文献复习，进一步提高对炎性乳腺癌的认识。方法：回顾性分析1例临床分期为T4dN1M0的炎性乳腺癌患者，新辅助化疗后行乳腺癌根治术，术后行放疗加内分泌治疗，观察其疗效，并回顾分析相关文献。结果：该炎性乳腺癌患者经新辅助化疗 + 手术、放疗 + 内分泌治疗，随诊至今患者暂无转移复发。
Abstract: Objective: Because inflammatory breast cancer is rare, and the initial symptom is often inflamma-tion, it is often misdiagnosed and missed in the diagnosis and treatment process. This article will further improve the understanding of inflammatory breast cancer through a case of inflammatory breast cancer with neoadjuvant chemotherapy and a literature review. Methods: A case of inflam-matory breast cancer with the clinical stage of T4dN1M0 was retrospectively analyzed. After neo-adjuvant chemotherapy, radical mastectomy was performed, followed by radiotherapy and endo-crine therapy. The efficacy was observed and the related literature was reviewed. Results: After neoadjuvant chemotherapy, surgery, radiotherapy, endocrinotherapy, the patient has no metasta-sis and recurrence.
文章引用：刘茹艳, 霍斌亮. 炎性乳腺癌1例[J]. 临床医学进展, 2022, 12(10): 9564-9568. https://doi.org/10.12677/ACM.2022.12101383

参考文献

[1] Chakraborty, P., George, J.T., Woodward, W.A., et al. (2021) Gene Expression Profiles of Inflammatory Breast Cancer Reveal High Heterogeneity across the Epithelial-Hybrid-Mesenchymal Spectrum. Translational Oncology, 14, Article ID: 101026. [Google Scholar] [CrossRef] [PubMed]
[2] Hance, K.W., Anderson, W.F., Devesa, S.S., et al. (2005) Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Re-sults Program at the National Cancer Institute. JNCI: Journal of the National Cancer Institute, 97, 966-975. [Google Scholar] [CrossRef] [PubMed]
[3] Yamauchi, H., Woodward, W.A., Valero, V., et al. (2012) Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist, 17, 891-899. [Google Scholar] [CrossRef] [PubMed]
[4] Masuda, H., Brewer, T.M., Liu, D.D., et al. (2014) Long-Term Treatment Efficacy in Primary Inflammatory Breast Cancer by Hormonal Receptor- and HER2-Defined Sub-types. Annals of Oncology, 25, 384-391. [Google Scholar] [CrossRef] [PubMed]
[5] Anderson, W.F., Schairer, C., Chen, B.E., et al. (2005) Epidemiology of Inflammatory Breast Cancer (IBC). Breast Disease, 22, 9-23. [Google Scholar] [CrossRef] 
[6] Pence, L.J., Kourtidis, A., Feathers, R.W., et al. (2021) PLEKHA7, an Apical Adherens Junction Protein, Suppresses Inflammatory Breast Cancer in the Context of High E-Cadherin and p120-Catenin Expression. International Journal of Molecular Sciences, 22, 1275. [Google Scholar] [CrossRef] [PubMed]
[7] Hester, R.H., Hortobagyi, G.N. and Lim, B. (2021) Inflammatory Breast Cancer: Early Recognition and Diagnosis Is Critical. Am J Obstet Gynecol, 225, 392-396. [Google Scholar] [CrossRef] [PubMed]
[8] 王欣冉, 张建国. 炎性乳腺癌的诊断与治疗进展[J]. 中国现代普通外科进展, 2019, 22(4): 308-311.
[9] Van Der Auwera, I., Limame, R., Van Dam, P., et al. (2010) Integrated miRNA and mRNA Expression Profiling of the Inflammatory Breast Cancer Subtype. British Journal of Cancer, 103, 532-541. [Google Scholar] [CrossRef] [PubMed]
[10] Lehman, H.L., Van Laere, S.J., Van Golen, C.M., et al. (2012) Regulation of Inflammatory Breast Cancer Cell Invasion through Akt1/PKBα Phosphorylation of RhoC GTPase. Molec-ular Cancer Research, 10, 1306-1318. [Google Scholar] [CrossRef] 
[11] Bozzetti, F., Saccozzi, R., De Lena, M., et al. (1981) In-flammatory Cancer of the Breast: Analysis of 114 Cases. Journal of Surgical Oncology, 18, 355-361. [Google Scholar] [CrossRef] [PubMed]
[12] Schlichting, J.A., Soliman, A.S., Schairer, C., et al. (2012) Inflam-matory and Non-Inflammatory Breast Cancer Survival by Socioeconomic Position in the Surveillance, Epidemiology, and End Results Database, 1990-2008. Breast Cancer Research and Treatment, 134, 1257-1268. [Google Scholar] [CrossRef] [PubMed]
[13] Bertucci, F., Ueno, N.T., Finetti, P., et al. (2014) Gene Expression Profiles of Inflammatory Breast Cancer: Correlation with Response to Neoadjuvant Chemotherapy and Metastasis-Free Survival. Annals of Oncology, 25, 358-365. [Google Scholar] [CrossRef] [PubMed]
[14] Genet, D., Lejeune, C., Bonnier, P., et al. (2007) Concomitant Inten-sive Chemoradiotherapy Induction in Non-Metastatic Inflammatory Breast Cancer: Long-Term Follow-Up. British Jour-nal of Cancer, 97, 883-887. [Google Scholar] [CrossRef] [PubMed]
[15] Perez, C.A., Graham, M.L., Taylor, M.E., et al. (1994) Management of Locally Advanced Carcinoma of the Breast. I. Noninflammatory. Cancer, 74, 453-465. [Google Scholar] [CrossRef] [PubMed]
[16] Dawood, S., Merajver, S.D., Viens, P., et al. (2011) International Expert Panel on Inflammatory Breast Cancer: Consensus Statement for Standardized Diagnosis and Treatment. Annals of Oncology, 22, 515-523. [Google Scholar] [CrossRef] [PubMed]
[17] Harvey, H.A., Lipton, A., Lawrence, B.V., et al. (1982) Estrogen Re-ceptor Status in Inflammatory Breast Carcinoma. Journal of Surgical Oncology, 21, 42-44. [Google Scholar] [CrossRef] [PubMed]
[18] Nguyen, D.M., Sam, K., Tsimelzon, A., et al. (2006) Molecular Het-erogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype. Clinical Cancer Research, 12, 5047-5054. [Google Scholar] [CrossRef] 
[19] Zell, J.A., Tsang, W.Y., Taylor, T.H., et al. (2009) Prog-nostic Impact of Human Epidermal Growth Factor-Like Receptor 2 and Hormone Receptor Status in Inflammatory Breast Cancer (IBC): Analysis of 2,014 IBC Patient Cases from the California Cancer Registry. Breast Cancer Research, 11, Article No. R9. [Google Scholar] [CrossRef] [PubMed]
[20] Walshe, J.M. and Swain, S.M. (2005) Clinical Aspects of In-flammatory Breast Cancer. Breast Disease, 22, 35-44. [Google Scholar] [CrossRef] 
[21] Harbeck, N. and Gnant, M. (2017) Breast Cancer. Lancet, 389, 1134-1150. [Google Scholar] [CrossRef] 
[22] Braal, C.L., Jongbloed, E.M., Wilting, S.M., et al. (2021) In-hibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs, 81, 317-331. [Google Scholar] [CrossRef] [PubMed]
[23] Slade, D. (2020) PARP and PARG Inhibitors in Cancer Treat-ment. Genes & Development, 34, 360-394. [Google Scholar] [CrossRef] [PubMed]
[24] Nunnery, S.E. and Mayer, I.A. (2020) Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. Drugs, 80, 1685-1697. [Google Scholar] [CrossRef] [PubMed]

为你推荐